국내 남성 전립선암 환자에서 다로루타마이드의 안전성을 알아보기 위한 관찰 연구
한국 환자에서 다로루타마이드 사용 승인에 대한 시판 후 감시 연구
This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a prostate cancer that has spread to other parts of the body and can be treated by lowering testosterone levels.
This study looks at the safety of the study drug, darolutamide, in Korean patients with nmCRPC or mHSPC. Darolutamide is currently available for doctors to prescribe to men with nmCRPC or mHSPC. It works by attaching to the special molecules called androgen receptors (AR) within prostate cells and blocks hormones called androgens from attaching to AR, which helps delay cancer growth.
To learn more about the safety of Darolutamide, the researchers will study whether the participants have adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The researchers will also learn more about how well darolutamide is working in these participants.
During this study, the researchers will collect information from the medical records of patients who have been prescribed darolutamide by their doctors.
Each participant will be in this study for 1 year. The whole study will last about 6 years. During this time, the participants will visit their doctor every 2 to 4 months as part of their usual care. At these visits, the doctors will do scans to check the patients' cancer and take blood samples. The patients will answer questions about any medications they are taking and whether they have any adverse events.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Bayer Clinical Trials Contact
- 전화번호: 0018888422937
- 이메일: clinical-trials-contact@bayer.com
연구 장소
-
-
-
Multiple Locations, 대한민국
- 모병
- Many locations
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients who have been prescribed Darolutamide for a medically appropriate use will be eligible to be enrolled.
설명
Inclusion Criteria:
-
Male aged ≥19 years
-
Patients with high risk nmCPRC
- Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dL])
- PSA doubling time < 10 months
-
Patients with mHSPC
- histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
- be candidates for androgen-deprivation therapy with/without docetaxel.
-
Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice
-
Written informed consent from subject or legal representative; assent from subject when appropriate
Exclusion Criteria:
- Patients participating in an investigational program with interventions outside of routine clinical practice
- Participants with contraindication according to the locally approved prescribing information
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Male patients with nmCRPC or mHSPC
Male patients with a diagnosis of non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be enrolled after the decision for treatment with Darolutamide has been made by the investigator. |
The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number, severity of adverse events (including SAEs)
기간: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
|
SAE stands for serious adverse event. An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment. |
From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
|
|
Number, severity of adverse drug reactions (including SADRs)
기간: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
|
SADR stands for serious adverse drug reaction. An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide. |
From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
|
|
The outcome of (serious) adverse events
기간: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
|
An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have a causal relationship with this treatment. |
From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
|
|
The outcome of (serious) adverse drug reactions
기간: From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
|
An ADR is any AE judged by investigator as having a reasonable suspected causal relationship to Darolutamide. |
From the date that the patient signed the informed consent to 30 days after the end of the treatment (up to 52 weeks)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
다롤루타마이드 종료 이유
기간: 최대 52주
|
최대 52주
|
|
|
다로루타마이드의 용량 및 용량 조절
기간: 최대 52주
|
최대 52주
|
|
|
Metastasis-free survival (MFS) by nmCRPC indication
기간: Up to 52 weeks
|
MFS is defined as the time (months) from the initiation of Darolutamide treatment to the date of first observed metastasis. |
Up to 52 weeks
|
|
Time to first symptomatic skeletal event (SSE) by nmCRPC indication
기간: Up to 52 weeks
|
Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event. |
Up to 52 weeks
|
|
Time to prostate-specific antigen (PSA) progression by nmCRPC indication
기간: Up to 52 weeks
|
Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir. |
Up to 52 weeks
|
|
Overall survival by nmCRPC indication
기간: Up to 52 weeks
|
Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause. |
Up to 52 weeks
|
|
Time to Castration-Resistant Prostate Cancer (CRPC) by mHSPC indication
기간: Up to 52 weeks
|
Time to mCRPC, defined as the time to PSA progression with serum testosterone being at castrate level <0.50 ng/mL, or the time to progression by soft tissue/visceral lesions or time to progression by bone lesions, whatever comes first. |
Up to 52 weeks
|
|
Time to first symptomatic skeletal event (SSE) by mHSPC indication
기간: Up to 52 weeks
|
Time to SSE is defined as the time (months) from the initiation of Darolutamide treatment to the date of first diagnosed skeletal-related event. |
Up to 52 weeks
|
|
Time to prostate-specific antigen (PSA) progression by mHSPC indication
기간: Up to 52 weeks
|
Time to PSA progression is defined as the time (months) from the initiation of Darolutamide treatment to the date at which PSA is recorded at ≥25% increase above the nadir (lowest screening or baseline) value along with an increase in absolute value of ≥2 ng/mL above nadir. |
Up to 52 weeks
|
|
Overall survival by mHSPC indication
기간: Up to 52 weeks
|
Overall survival is defined as the time (months) from the initiation of Darolutamide treatment until death from any cause. |
Up to 52 weeks
|
|
Time to initiation of subsequent anti-cancer therapy by mHSPC indication
기간: Up to 52 weeks
|
Time to initiation of subsequent anti-cancer therapy is defined as the time (months) from the initiation of Darolutamide treatment to the date of first administration of any subsequent anti-cancer therapy after discontinuation of Darolutamide. |
Up to 52 weeks
|
|
Radiological progression (Soft tissue/ Bone metastasis) by mHSPC indication
기간: Up to 52 weeks
|
Radiological progression is defined as the time (months) from the start of Darolutamide treatment to the date of first documentation of radiological progressive disease or death due to any cause, whichever occurs first. |
Up to 52 weeks
|
|
Radiological Progression-Free Survival (rPFS) by mHSPC indication
기간: Up to 52 weeks
|
Radiographic Progression-Free Survival (rPFS) is defined as the time (months) from the initiation of Darolutamide treatment to the date of the first radiologically confirmed disease progression or death from any cause, whichever occurs first. |
Up to 52 weeks
|
|
Duration of Darolutamide treatment
기간: Up to 52 weeks
|
Duration of Darolutamide treatment is defined as the time (months) from the start of Darolutamide treatment to the day of permanent discontinuation of Darolutamide (including death). |
Up to 52 weeks
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 20654
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .